Cleary, J. M., Rosen, L. S., Yoshida, K., Rasco, D., Shapiro, G. I., & Sun, W. (2017). A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone. Invest New Drugs.
Citação norma ChicagoCleary, James M., Lee S. Rosen, Kenichiro Yoshida, Drew Rasco, Geoffrey I. Shapiro, and Weijing Sun. "A Phase 1 Study of the Pharmacokinetics of Nucleoside Analog Trifluridine and Thymidine Phosphorylase Inhibitor Tipiracil (components of TAS-102) Vs Trifluridine Alone." Invest New Drugs 2017.
Citação norma MLACleary, James M., et al. "A Phase 1 Study of the Pharmacokinetics of Nucleoside Analog Trifluridine and Thymidine Phosphorylase Inhibitor Tipiracil (components of TAS-102) Vs Trifluridine Alone." Invest New Drugs 2017.